23 December 2021
Dataprep Holdings Bhd’s subsidiary has been appointed as the project delivery partner for the outsourcing of integrated solutions for Covid-19 rapid molecular testing.
In a bourse filing on Thursday (Dec 23), Dataprep said its subsidiary Dataprep Asia Sdn Bhd had received the letter of consent from the Ministry of Health to commence the trial run of Covid-19 screening RT-PCR testing under the MiCo BioMed brand.
It said testing will be conducted specifically at the country’s main international entry points, such as the Kuala Lumpur International Airport (KLIA), klia2, the Langkawi International Airport, the Senai International Airport and Tambak Johor (the Johor-Singapore Causeway).
It said that the deployment of the Covid-19 screening will cover the registration, sampling and testing until the issuance of the test result.
Dataprep group managing director Mohamad Sabir Mohamad Sabri said that the group is prepared to support the government in the process of reopening the borders and is confident it can be implemented efficiently and safely.
“Barring any unforeseen circumstances, the deployment of MiCo BioMed Covid-19 rapid molecular testing using molecular diagnostics equipment by Dataprep Asia is expected to contribute positively to the earnings per share and net assets per share of Dataprep Group for the financial year ending Dec 31, 2022 and onwards,” he said in a statement.
Dataprep said the deployment of testing is expected to contribute positively to its earnings for the financial year ending Dec 31, 2022 and onwards.
At the midday break on Thursday, Dataprep had shed 1.5 sen to 84 sen, valuing it at RM563.19 million.